Conference Track

HCV Management: Facing New Challenges

Source: CCO Independent Conference Coverage of the 2005 Annual Meeting of the American Association for the Study of Liver Diseases*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

High-Dose Ribavirin plus Peginterferon With Epoetin Alfa Leads to Higher Sustained Virologic Response for HCV Genotype 1
Shorter Treatment With Peginterferon Alfa-2a Plus Ribavirin Possible In HCV Genotype 1 'Super-Responders'?
Some HCV-Infected Interferon Nonresponders/ Relapsers Achieve Sustained Virologic Response Following 48-Week Retreatment With Peginterferon Alfa-2b Plus Ribavirin
SCH 503034 Demonstrated Potent Activity in Genotype 1 HCV Patients Previously Failing Peginterferon
24-Weeks of Peginterferon plus Ribavirin Safe and Effective for Acute Hepatitis C in HIV-Positive Patients
Valopicitabine Plus Peginterferon Alfa-2a Highly Effective at Suppressing HCV in Peginterferon Plus Ribavirin Nonresponders
HCV NS34A Protease Inhibitor VX-950 Safe, Highly Effective in HCV-Infected Patients
Novel Compound CPG 10101 Stimulates Immunity and Reduces Viral Load in HCV-Infected Patients
Black Patients With HCV Genotype 1 Less Likely Than Whites to Respond to Peginterferon Alfa Plus Ribavirin
SCH 503034 Plus Peginterferon Exhibit Activity Against HCV in Previous Nonresponders in Phase 1 Study
Interferon-Experienced Chronic Hepatitis C Patients Tolerate Long-Acting Albuferon in Interim Analysis of Phase 2 Trial
Epoetin Not Cost-Effective for HCV Treatment-Related Anemia
Universal HIV Testing Recommended for HCV-Positive Individuals
Peginterferon Alfa-2a Plus Ribavirin Highly Cost-Effective for HCV Nongenotype 1 in Patients Coinfected With HIV-1
Sustained Virologic Response After Interferon Monotherapy Associated With Lower Risk of HCC and Mortality in Patients With HCV-Related Child’s Class A Cirrhosis
Higher Prevalence of Sexual Dysfunction and Depression in Men With Chronic Hepatitis C
Rapid Virologic Response by Week 4 Predictive of Sustained Response Following 24 Weeks of Treatment in HCV Genotype 1 Patients
High-Dose Peginterferon Superior to Standard-Dose Regimen as Induction Therapy After Treatment Failure
Characterization of Resistance Mutations Selected by Protease Inhibitor VX-950
High-Dose Peginterferon Alfa-2b Plus Weight-Based Ribavirin More Effective in Achieving Sustained Virologic Response Rate in Previous HCV Nonresponders
Consensus Interferon-Containing Regimens Suppress HCV Genotype 1 in Chronically Infected Patients
Interferon Alfacon-1 Plus Interferon Gamma-1b Combination Therapy Has Similar Anti-HCV Effect Across Racial Groups
Optimizing Ribavirin Dose by Patient Weight Enhances Sustained Viral Responses in Patients With Chronic Hepatitis C

Expert Analysis

HCV Management: Facing New Challenges

Faculty:
Gary L. Davis, MD Jean-Michel Pawlotsky, MD, PhD Mitchell L. Shiffman, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe the impact of sustained virologic response to interferon-based treatment in the subsequent development of hepatocellular carcinoma and death
Review the results of recent studies evaluating the use of peginterferon/ribavirin combinations, including higher than typical dosages, for treatment of previous nonresponders to HCV therapy
Evaluate the results of trials of drugs in development for treatment of HCV infection

CME CREDIT INFORMATION

Release Date: 02/09/06

Expiration Date: 02/08/07

Physicians: maximum of 1.5 AMA PRA Category 1 Credit(s)™

Registered Nurses: 1.9 Nursing CE credits

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.